A randomized trial of intravitreal bevacizumab vs ranibizumab for myopic CNV.

Salvatore Cillino, Domenica Matranga, Maria Vadala', Giuseppe Fasolino, Paolo Milani, Alfredo Pece, Costantino John Trombetta, Giuseppe De Crecchio, Costantino John Trombetta, Carla Monteleone

Risultato della ricerca: Articlepeer review

11 Citazioni (Scopus)

Abstract

ABSTRACTAims: To compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM).Methods: A prospective multicenter randomized not-blinded trial.Results: In seven centers 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an ”on demand” regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p=0.0009 and p=0.0002 respectively). In group B mean basal BCVA was 0.52 logMAR (20/63 Seq) and 54 ls and final BCVA was 0.51 logMar (20/63 Seq) and 57 ls. In group R mean basal BCVA was 0.62 logMAR (20/80 Seq) and 45 ls and final values were 0.50 logMAR (20/63 Seq) and 58 ls. Statistical comparison of the two groups showed no significant difference (logMAR p=0.90 and letters p=0.78). Multivariate analysis showed no influence of age or previous photodynamic treatment (PDT) on final visual changes. The mean number of treatments in the first year was 2.7 in group B and 2.3 in group R (p=0.09). Conclusion: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.
Lingua originaleEnglish
pagine (da-a)1867-1872
Numero di pagine6
RivistaGraefe's Archive for Clinical and Experimental Ophthalmology
Volume253
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Entra nei temi di ricerca di 'A randomized trial of intravitreal bevacizumab vs ranibizumab for myopic CNV.'. Insieme formano una fingerprint unica.

Cita questo